U.S. Point of Care (PoC) Diagnostics Market Size, Share, Trends, & Industry Analysis Report By Product (Glucose Testing, Hb1Ac Testing, Coagulation), By Mode of Prescription, By End Use – Market Forecast, 2025–2034

Publisher Polaris Market Research & Consulting LLP

Published Sep 01, 2025

Length 126 Pages

SKU # PLRS20451553

Description

The U.S. point-of-care (PoC) diagnostics market size is expected to reach USD 18.83 billion by 2034, according to a new study by Polaris Market Research. The report “U.S. Point of Care (PoC) diagnostics Market Share, Size, Trends, Industry Analysis Report: By Product (Glucose Testing, Hb1Ac Testing, Coagulation), By Mode of Prescription, and By End Use; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Point-of-Care (PoC) diagnostics are rapid diagnostics that provide testing and diagnosis as close to the patient as possible and with the timeliness to provide clinical decision support. The market is driven by the increased connectivity of decentralized testing, thereby decreasing reliance on centralized labs while also supporting immediate diagnosis of patients regardless of the location of health care services. These new testing solutions provide enhanced support for care delivery of new testing and diagnosis while enabling quick treatment and improved turnaround times. Improving outcomes allows for quicker intervention when necessary, contributing to the goal of providing accessible and appropriate healthcare to all patients. PoC diagnostics will expand the use case of decentralized diagnostic testing and shape the future healthcare environments.

The U.S. market growth is driven by the ongoing advances in this area of PoC diagnostics that relate to performance, connectivity, and usability. Innovations in the market, such as digitally connected devices, smaller portable medical devices, and refined molecular platforms, deliver better performance and more useful forms of testing. The more recent innovations improve healthcare workflows by allowing the user to extract and efficiently integrate results directly into the patient’s EHRs, improving clinical monitoring and increasing the efficiency of the care team. PoC diagnostics is well-positioned to provide reliable and real-time results, making it an important driver of better healthcare outcomes with these types of innovations being regularly introduced.

U.S. Point-of-Care (PoC) diagnostics Market Report Highlights

In terms of product, in 2024, the infectious diseases segment accounted for 36.91% revenue share in 2024 due to the increasing demand for accurate and rapid detection of diseases.

Based on mode of prescription, the OTC segment is expected to witness growth at a CAGR of 1.8% during the forecast period driven by the increasing patient demand for monitoring and self-testing.

In terms of end use, the clinics segment held 36.82% share of the market in 2024 owing to their role in delivering rapid diagnostic services to a wide patient base.

A few global key market players include Abbott; Agilent Technologies, Inc.; BD; BIOMÉRIEUX; Danaher Corporation; Hologic, Inc.; Illumina, Inc.; Quest Diagnostics Incorporated; QuidelOrtho Corporation; and Thermo Fisher Scientific Inc.

Polaris Market Research has segmented the market report on the basis of product, mode of prescription, and end use:

By Product Outlook (Revenue, USD Billion, 2020–2034)

Glucose Testing

Hb1Ac Testing

Coagulation

Fertility

Infectious Diseases

HIV

Clostridium Difficile

HBV

Pneumonia or Streptococcus Associated Infections

Respiratory Syncytial Virus (RSV)

HPV

Influenza/Flu

HCV

MRSA

TB and Drug-Resistant TB

HSV

Others

Cardiac Markers

Thyroid Stimulating Hormone

Hematology

Primary Care Systems

Decentralized Clinical Chemistry

Feces

Lipid Testing

Cancer Marker

Blood Gas/Electrolytes

Ambulatory Chemistry

Drug Abuse Testing

Urinalysis

By Mode of Prescription (Revenue, USD Billion, 2020–2034)

OTC

Prescription-based

By End Use Outlook (Revenue, USD Billion, 2020–2034)

Clinics

Physician Office

Pharmacy & Retail Clinics

Non-practice Clinics

Urgent Care Clinic

Hospitals

Home

Assisted Living Healthcare Facilities

Laboratory

1. Introduction: 1.1. Report Description; 1.1.1. Objectives of the Study; 1.1.2. Market Scope; 1.1.3. Assumptions; 1.2. Stakeholders
2. Executive Summary: 2.1. Market Highlights
3. Research Methodology: 3.1. Overview; 3.1.1. Data Mining; 3.2. Data Source; 3.2.1. Primary Source; 3.2.2. Secondary Source
4. U.S. C-Reactive Protein Testing Market Insights: 4.1. C-Reactive Protein Testing Market – Market Snapshot; 4.2. C-Reactive Protein Testing Market Dynamics; 4.2.1. Drivers and Opportunities; 4.2.1.1. Increasing Demand for Precision Medicine; 4.2.1.2. Increasing Burden of Chronic Diseases such as Cardiovascular Disorders; 4.2.2. Restraints and Challenges; 4.2.2.1. Lack of Specificity; 4.3. Porter’s Five Forces Analysis; 4.3.1. Bargaining Power of Suppliers (Moderate); 4.3.2. Threats of New Entrants: (Low); 4.3.3. Bargaining Power of Buyers (Moderate); 4.3.4. Threat of Substitute (Moderate); 4.3.5. Rivalry among existing firms (High); 4.4. PESTEL Analysis; 4.5. C-Reactive Protein Testing Market Trends; 4.6. Value Chain Analysis
5. U.S. C-Reactive Protein Testing Market, by Assay Type: 5.1. Key Findings; 5.2. Introduction; 5.2.1. U.S. C-Reactive Protein Testing Market, by Assay Type, 2020-2034 (USD Million); 5.3. Immuno-turbidimetric Assay; 5.3.1. U.S. C-Reactive Protein Testing Market, by Immuno-turbidimetric Assay, by Region, 2020-2034 (USD Million); 5.4. ELISA; 5.4.1. U.S. C-Reactive Protein Testing Market, by ELISA, by Region, 2020-2034 (USD Million); 5.5. Clinical; 5.5.1. U.S. C-Reactive Protein Testing Market, by Clinical, by Region, 2020-2034 (USD Million); 5.6. Non-clinical; 5.6.1. U.S. C-Reactive Protein Testing Market, by Non-clinical, by Region, 2020-2034 (USD Million); 5.7. Chemiluminescence Immunoassay; 5.7.1. U.S. C-Reactive Protein Testing Market, by Chemiluminescence Immunoassay, by Region, 2020-2034 (USD Million); 5.8. Others; 5.8.1. U.S. C-Reactive Protein Testing Market, by Others, by Region, 2020-2034 (USD Million)
6. U.S. C-Reactive Protein Testing Market, by Detection Range: 6.1. Key Findings; 6.2. Introduction; 6.2.1. U.S. C-Reactive Protein Testing Market, by Detection Range, 2020-2034 (USD Million); 6.3. hs (high sensitivity) CRP; 6.3.1. U.S. C-Reactive Protein Testing Market, by hs (high sensitivity) CRP, by Region, 2020-2034 (USD Million); 6.4. Conventional CRP; 6.4.1. U.S. C-Reactive Protein Testing Market, by Conventional CRP, by Region, 2020-2034 (USD Million); 6.5. cCRP; 6.5.1. U.S. C-Reactive Protein Testing Market, by cCRP, by Region, 2020-2034 (USD Million)
7. U.S. C-Reactive Protein Testing Market, by Disease Area: 7.1. Key Findings; 7.2. Introduction; 7.2.1. U.S. C-Reactive Protein Testing Market, by Disease Area, 2020-2034 (USD Million); 7.3. Cardiovascular Diseases; 7.3.1. U.S. C-Reactive Protein Testing Market, by Cardiovascular Diseases, by Region, 2020-2034 (USD Million); 7.4. Cancer; 7.4.1. U.S. C-Reactive Protein Testing Market, by Cancer, by Region, 2020-2034 (USD Million); 7.5. Rheumatoid Arthritis; 7.5.1. U.S. C-Reactive Protein Testing Market, by Rheumatoid Arthritis, by Region, 2020-2034 (USD Million); 7.6. Inflammatory Bowel Disease; 7.6.1. U.S. C-Reactive Protein Testing Market, by Inflammatory Bowel Disease, by Region, 2020-2034 (USD Million); 7.7. Endometriosis; 7.7.1. U.S. C-Reactive Protein Testing Market, by Endometriosis, by Region, 2020-2034 (USD Million); 7.8. Lupus; 7.8.1. U.S. C-Reactive Protein Testing Market, by Lupus, by Region, 2020-2034 (USD Million); 7.9. Others; 7.9.1. U.S. C-Reactive Protein Testing Market, by Others, by Region, 2020-2034 (USD Million)
8. U.S. C-Reactive Protein Testing Market, by End Use: 8.1. Key Findings; 8.2. Introduction; 8.2.1. U.S. C-Reactive Protein Testing Market, by End Use, 2020-2034 (USD Million); 8.3. Clinics; 8.3.1. U.S. C-Reactive Protein Testing Market, by Clinics, by Region, 2020-2034 (USD Million); 8.4. Hospitals; 8.4.1. U.S. C-Reactive Protein Testing Market, by Hospitals, by Region, 2020-2034 (USD Million); 8.5. Laboratories; 8.5.1. U.S. C-Reactive Protein Testing Market, by Laboratories, by Region, 2020-2034 (USD Million); 8.6. Assisted Living Healthcare Facilities; 8.6.1. U.S. C-Reactive Protein Testing Market, by Assisted Living Healthcare Facilities, by Region, 2020-2034 (USD Million); 8.7. Home Care Settings; 8.7.1. U.S. C-Reactive Protein Testing Market, by Home Care Settings, by Region, 2020-2034 (USD Million); 8.8. Others; 8.8.1. U.S. C-Reactive Protein Testing Market, by Others, by Region, 2020-2034 (USD Million)
9. Competitive Landscape: 9.1. Expansion and Acquisition Analysis; 9.1.1. Expansion; 9.1.2. Acquisitions; 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles: 10.1. Abbott Laboratories; 10.1.1. Company Overview; 10.1.2. Financial Performance; 10.1.3. Product Benchmarking; 10.1.4. Recent Development; 10.2. Boditech Med; 10.2.1. Company Overview; 10.2.2. Financial Performance; 10.2.3. Product Benchmarking; 10.2.4. Recent Development; 10.3. F. Hoffmann-La Roche Ltd; 10.3.1. Company Overview; 10.3.2. Financial Performance; 10.3.3. Product Benchmarking; 10.3.4. Recent Development; 10.4. Getein Biotech; 10.4.1. Company Overview; 10.4.2. Financial Performance; 10.4.3. Product Benchmarking; 10.4.4. Recent Development; 10.5. HORIBA Ltd; 10.5.1. Company Overview; 10.5.2. Financial Performance; 10.5.3. Product Benchmarking; 10.5.4. Recent Development; 10.6. Merck KGaA; 10.6.1. Company Overview; 10.6.2. Financial Performance; 10.6.3. Product Benchmarking; 10.6.4. Recent Development; 10.7. Quest Diagnostics Incorporated; 10.7.1. Company Overview; 10.7.2. Financial Performance; 10.7.3. Product Benchmarking; 10.7.4. Recent Development; 10.8. Randox Laboratories; 10.8.1. Company Overview; 10.8.2. Financial Performance; 10.8.3. Product Benchmarking; 10.8.4. Recent Development; 10.9. Siemens Healthineers; 10.9.1. Company Overview; 10.9.2. Financial Performance; 10.9.3. Product Benchmarking; 10.9.4. Recent Development; 10.10. Thermo Fisher Scientific, Inc.; 10.10.1. Company Overview; 10.10.2. Financial Performance; 10.10.3. Product Benchmarking; 10.10.4. Recent Development

Pricing

Currency Rates

Single User Email from Publisher $4,250
Global Site License Email from Publisher $6,250

How Do Licenses Work?

Request A Sample

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now